Media coverage about Checkpoint Therapeutics (NASDAQ:CKPT) has been trending somewhat negative on Wednesday, Accern Sentiment reports. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Checkpoint Therapeutics earned a news impact score of -0.05 on Accern’s scale. Accern also gave news articles about the company an impact score of 48.0759449645648 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Checkpoint Therapeutics (CKPT) opened at 7.12 on Wednesday. The firm has a 50-day moving average price of $8.38 and a 200-day moving average price of $8.74. The stock’s market cap is $180.62 million. Checkpoint Therapeutics has a 12 month low of $5.00 and a 12 month high of $15.00.
TRADEMARK VIOLATION NOTICE: “Somewhat Critical Media Coverage Somewhat Unlikely to Impact Checkpoint Therapeutics (CKPT) Stock Price” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://sportsperspectives.com/2017/09/13/somewhat-critical-media-coverage-somewhat-unlikely-to-impact-checkpoint-therapeutics-ckpt-stock-price.html.
Checkpoint Therapeutics Company Profile
Checkpoint Therapeutics, Inc is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies.
Receive News & Ratings for Checkpoint Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.